FDAnews Drug Daily Bulletin

Pharma Blog Watch

Aug. 22, 2012
A A
Pharma Spending On Outcomes Research Rises (Pharmalot Blog)
“Once upon a time, winning FDA approval for a drug was considered the gold standard,” blogger Ed Silverman writes. Now, drugmakers are looking for payers to provide coverage, leading to an increase in spending on health economics and outcomes research. “At the 50 largest drugmakers, for instance, spending levels average $7.5 million, with budgets growing nearly across the board,” Silverman writes, adding “in the U.S., economics and outcomes research is typically being used to support 10 brands, although the 20 largest drugmakers are supporting nearly 20 brands.”